Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Circulation Journal

• Publication date

  2010-10-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1253/CIRCJ.CJ-09-0759PMID 20877128
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From 4-links to 5-links of "chain of survival". Post-resuscitation care is critical for good neurological recovery.

  2009cited by this paper
• Patient selection and therapeutic strategy for emergency percutaneous cardiopulmonary system in cardiopulmonary arrest patients.

  2009cited by this paper
• Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome.

  2009cited by this paper
• Effect of hypothermia therapy after outpatient cardiac arrest due to ventricular fibrillation.

  2009cited by this paper
• Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis.

  2008cited by this paper
• Effectiveness of Bystander-Initiated Cardiac-Only Resuscitation for Patients With Out-of-Hospital Cardiac Arrest

  2007cited by this paper
• Prevention of Life-Threatening Ventricular Tachyarrhythmia by a Novel and Pure Class-III Agent, Nifekalant Hydrochloride

  2006cited by this paper
• Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation.

  2006cited by this paper
• Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? : comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis.

  2006cited by this paper
• Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation.

  2005cited by this paper
• Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization.

  2004cited by this paper
• The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs.

  2002cited by this paper
• Amiodarone compared with lidocaine for shock-resistant ventricular fibrillation

  2002cited by this paper
• Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation.

  2002cited by this paper
• [Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug].

  2002cited by this paper
• Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model.

  2001cited by this paper
• Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

  2000cited by this paper
• Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation.

  1999cited by this paper
• Evidence-based analysis of amiodarone efficacy and safety.

  1999cited by this paper
• Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.

  1998cited by this paper
• Electrophysiological Effects of MS-551 , a New Class III Agent : Comparison with dl-Sotalol in Dogs 1

  1998cited by this paper
• Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?

  1997cited by this paper
• Cellular electrophysiological effects of MS‐551, a new class III antiarrhythmic agent

  1995cited by this paper
• Effects of MS-551, a New Class III Antiarrhythmic Drug, on Programmed Stimulation-Induced Ventricular Arrhythmias, Electrophysiology, and Hemodynamics in a Canine Myocardial Infarction Model

  1994cited by this paper
• Hemodynamics of cardiac massage.

  1983cited by this paper
• Hemodynamics of cardiac massage.

  1983cited by this paper

• Preventive Effect of Nifekalant on Recurrent Ventricular Fibrillation and Electrical Storm　― A Systematic Review and Meta-Analysis ―

  2025cites this paper
• Anesthetic management of a patient with severe aortic regurgitation undergoing reoperation for ascending aorta false aneurysm using hypothermia: prevention of ventricular fibrillation by nifekalant

  2021cites this paper
• Nifekalant: A New Option for Pre-Excited Atrial Fibrillation With a High-Risk Accessory Pathway.

  2020cites this paper
• Nifekalant

  2020cites this paper
• Drugs in cardiac arrest: the rise and fall of antiarrhythmics

  2018cites this paper
• [Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone].

  2016cites this paper
• Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation

  2015cites this paper
• Effects of pH on nifekalant-induced electrophysiological change assessed in the Langendorff heart model of guinea pigs.

  2014cites this paper
• Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation

  2014cites this paper
• QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias: Post‐hoc analysis from a large‐scale multicenter post‐marketing survey in Japan

  2013cites this paper
• An HPLC method for the determination of nifekalant hydrochloride in canine plasma and its application to a pharmacokinetic study.

  2013cites this paper
• Impact of early intravenous epinephrine administration on outcomes following out-of-hospital cardiac arrest.

  2012cites this paper
• Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias.

  2011cites this paper
• Drugs during cardiopulmonary resuscitation

  2011cites this paper
• Current Pharmacological Advances in the Treatment of Cardiac Arrest

  2011cites this paper
• Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm.

  2010cites this paper